Results 41 to 50 of about 13,843 (217)

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

open access: yesSAGE Open Medical Case Reports, 2021
Palmoplantar pustulosis or palmoplantar pustular psoriasis is chronic skin conditions, characterised by eruptions of sterile pustules on an erythematosquamous background. High-quality data on the treatment of palmoplantar pustulosis are limited, and none
Maruška Marovt, Pij B Marko
doaj   +1 more source

Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review. [PDF]

open access: yesAnn Med
Background Palmoplantar pustulosis (PPP) is a chronic, relapsing inflammatory dermatosis characterized by recurrent sterile pustules localized to the palms and soles, accompanied by significant pain and psychological burden.
Vimbai Chirindo C   +4 more
europepmc   +2 more sources

The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study

open access: yesEfficacy and Mechanism Evaluation, 2022
Background: Palmoplantar pustulosis is a rare, debilitating, chronic skin disease involving the hands and feet, and there are limited treatment options. Mechanistic findings suggest that interleukin 1 may be a pathogenic driver.
Suzie Cro   +12 more
doaj   +1 more source

Recent advances in palmoplantar pustulosis [PDF]

open access: yesFaculty Reviews, 2021
Palmoplantar pustulosis (PPP) is a chronic inflammatory condition where crops of sterile pustules with erythematous keratotic lesions causing bleeding and pain appear on the palms and soles. Recently, the European Rare and Severe Expert Network considered PPP as a variant of pustular psoriasis with or without psoriasis vulgaris.
Brunasso, Alexandra Maria Giovanna   +1 more
openaire   +2 more sources

Emerging Therapies for Palmoplantar Pustulosis with a Focus on IL-23 Inhibitors. [PDF]

open access: yesJ Clin Med
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterized by recurrent pustules, erythema, and scaling on the palms and soles, leading to a significantly reduced quality of life.
Nam KH, Kim YS.
europepmc   +2 more sources

Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study. [PDF]

open access: yesJ Dermatol
Palmoplantar pustulosis (PPP) is a chronic, debilitating skin disease of the palms and/or soles. We report the efficacy and safety of risankizumab (RZB), an interleukin 23 p19 inhibitor, from the JumPPP study (a phase 3, multicenter, randomized, placebo ...
Okubo Y   +11 more
europepmc   +2 more sources

Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis [PDF]

open access: yes, 2023
BACKGROUND: This review’s goals were to investigate apremilast’s efficacy versus placebo in palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP), and apremilast’s efficacy versus methotrexate in PP.
Spencer, Riley K.   +10 more
core   +1 more source

Pustulosis palmoplantar: a propósito de un caso [PDF]

open access: yesAtención Primaria
Sara de Antonio Feu   +2 more
doaj   +2 more sources

Th17 cells with regulatory phenotype are the main IL-17F and IL-26 producers in palmoplantar pustulosis. [PDF]

open access: yesJCI Insight
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disorder marked by erythematous pustules and desquamation on the palms and soles. While IL-17 pathways are implicated in PPP, IL-17 blockers have shown modest efficacy, underscoring the need ...
Do TH   +18 more
europepmc   +2 more sources

Palmoplantar pustulosis associated with membranous glomerulonephritis

open access: yesIndian Dermatology Online Journal, 2021
Vishal Thakur   +3 more
doaj   +3 more sources

Home - About - Disclaimer - Privacy